0001209191-19-011187.txt : 20190219 0001209191-19-011187.hdr.sgml : 20190219 20190219170822 ACCESSION NUMBER: 0001209191-19-011187 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190215 FILED AS OF DATE: 20190219 DATE AS OF CHANGE: 20190219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haqq Christopher CENTRAL INDEX KEY: 0001612095 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 19615907 MAIL ADDRESS: STREET 1: C/O ATARA BIOTHERAPEUTICS, INC. STREET 2: 3260 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-278-8930 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-15 0 0001604464 Atara Biotherapeutics, Inc. ATRA 0001612095 Haqq Christopher 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP, R&D & Chief Scientific Of Common Stock 2019-02-15 4 S 0 775 39.59 D 271943 D Common Stock 17312 I See footnote Common Stock 2688 I See footnote Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.33 to $39.695. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee. The shares are held by The Havenside Trust, of which the Reporting Person is trustee. /s/ David Tucker, Attorney-in-Fact for Christopher Haqq 2019-02-19